[What progress can be expected in the management of hypertension? Forecast from 1974 to 2034].
THE POSITIVE IMPACT OF TREATMENT: Antihypertensive treatments have clearly demonstrated their capacity to reduce cardiovascular mortality. The limits to the reduction in risk are imputable to insufficient early management, morbidity and poor compleance insufficiency of pharmacological treatments, absence of individualised adaptation to the causal pathology and inappropriate management of other cardiovascular risk factors. TO IMPROVE MANAGEMENT: Rather than creating more cardiovascular prevention Centres which only concern specific cases and research, it is fundamental to provide physicians, nurses and other health care workers with greater competence in hypertension and the management of cardiovascular risks. Conceptual changes are also necessary, particularly in that which concerns the end of the dichotomy between normotension and hypertension, hypercholesterolemia and normocholesterolemia and its individual and populational impact. PROMOTION OF NUTRITIONAL MEANS: Nutritional means should not be forgotten applied to accompany the whole pharmacological treatment of hypertension, they can be used for individual prevention and for reduction of the incidence of high blood pressure in the general population. NEW THERAPEUTIC STRATEGIES: Other than the search for antihypertensive drugs with greater efficacy and improved tolerance, several targets should be envisaged such as optimising the blockage of the renin-angiotensin-aldosterone system, inihibiting aldo-synthase. A CONSERVATIVE ATTITUDE: Although attractive, the individualisation of treatment based on genetic analysis will not be accessible to the majority of hypertensive patients. The attitude to be considered in 2004 consists above all in improving the use of available drugs at appropriate doses and especially in combinations at fixed-doses to allow for an easier therapeutic schedule.
Ménard
Joël
J
Faculté de médecine, Broussais-Hôtel Dieu, Santé publique et informatique médicale, Paris.
D000959:Antihypertensive Agents / Q000627:therapeutic use; D001291:Attitude of Health Personnel; D002309:Cardiology / Q000592:standards / Q000639:trends; D002983:Clinical Competence; D003695:Delivery of Health Care / Q000458:organization & administration; D005544:Forecasting; D005602:France / Q000453:epidemiology; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000523:psychology / Q000628:therapy*; D015994:Incidence; D008019:Life Style; D009017:Morbidity; D020380:Needs Assessment; D009747:Nutritional Physiological Phenomena; D009936:Organizational Innovation; D010348:Patient Care Team / Q000458:organization & administration; D010349:Patient Compliance; D010818:Practice Patterns, Physicians' / Q000592:standards / Q000639:trends; D011322:Primary Prevention; D012307:Risk Factors; D017749:Total Quality Management / Q000458:organization & administration; D016896:Treatment Outcome
D000959:Antihypertensive Agents